News
CHMP recommends a change to indication for Tecentriq in NSCLC.- Genentech/Roche
The CHMP adopted a new indication for the treatment of early-stage non-small cell lung cancer (NSCLC). The additional indication for Tecentriq will be: Early-stage non-small cell lung cancer (NSCLC). Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on at least 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.
Condition: Non Small Cell Lung Cancer
Type: drug